Epilepsy Surgery in Children: Overview

Status: draft · Last updated 2026-11-16 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Drug resistance = failure of two appropriate medications. A third drug rarely works (about 11% after a first failure for lack of efficacy) .
  • Refer early:
    • as soon as drug resistance is established;
    • or with a lesion in noneloquent cortex even if seizures are controlled .
    • Evaluation within 1 year roughly doubles seizure freedom .
  • An MRI lesion predicts intractability in childhood temporal lobe epilepsy . Onset in the first year carries the highest cognitive risk .
  • Commonest pediatric substrates: cortical dysplasia (42%) and tumors (19%) .
  • Expect:
    • about 65% seizure-free at 1 year, falling over a decade;
    • better results after hemispheric and temporal surgery and with complete resection ;
    • surgery beats medication 77% vs. 7% .

Landmark papers

  • Dwivedi et al., N Engl J Med 2017: pediatric randomized trial of surgery vs medical therapy. 77% of children were seizure-free at 12 months after surgery vs 7% on medical therapy .
  • ILAE drug resistance definition (Kwan et al., Epilepsia 2010): consensus proposal defining drug resistance as seizure freedom not sustained despite adequate trials of two well-tolerated, appropriate antiseizure medications .
  • Kwan and Brodie, N Engl J Med 2000: cohort of 525 newly diagnosed patients. Among the 470 previously untreated, 47% became seizure-free on the first drug, a further 14% on a second or third, and about 3% on two drugs together .

Epilepsy surgery is the most effective treatment for drug-resistant focal epilepsy in children, and it is underused and delayed.

Jason S. Hauptman, MD, PhD© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure from Hauptman's High Yield Thoughts in Pediatric Neurosurgery (pedsneurosurg.org). Do not copy, reproduce, redistribute or adapt without written permission.https://www.pedsneurosurg.org/hy-peds-ns:epilepsy_surgery_pathway:b739d0467c5b531b© 2026 Jason S. Hauptman, MD, PhD. All rights reserved. Original figure; please do not copy, reproduce or redistribute without written permission.Flow diagram: drug-resistant epilepsy or a lesion in noneloquent cortex leads to early referral, noninvasive phase 1 evaluation and a multidisciplinary conference, then concordant cases to resection, ablation or disconnection, discordant or MRI-negative cases to invasive phase 2 monitoring, and generalized or multifocal cases to palliative proceduresPEDIATRIC EPILEPSY SURGERY PATHWAYDrug-resistant epilepsy2 adequate ASM trials failedOR a lesion in noneloquentcortex, even if seizure-freeon 1–2 ASMsRefer earlyto a comprehensive pediatricepilepsy center(within 1 year)Phase 1 (noninvasive)video-EEG3T epilepsy-protocol MRIPET / SPECT / MEGneuropsychology, fMRIMultidisciplinary conferencedata reviewed together; plan agreedA Concordant focusresection, LITT ordisconnection:temporal, extratemporal,hemisphericB Discordant / MRI-negativePhase 2 invasive:stereo-EEG or grids→ resection / ablationC Generalized / multifocalnot localizable → palliative:callosotomy, VNS,RNS, DBSASM, antiseizure medication; LITT, laser interstitial thermal therapy; VNS, vagus nerve stimulation;RNS, responsive neurostimulation; DBS, deep brain stimulation
Pediatric epilepsy surgery pathway. Drug-resistant epilepsy, or a lesion in noneloquent cortex even when seizures are controlled, prompts referral to a comprehensive center within a year. Noninvasive phase 1 workup and multidisciplinary conference lead to resective, ablative or disconnective surgery for a concordant focus; to invasive phase 2 monitoring (stereo-EEG) for discordant or MRI-negative cases; or to palliative callosotomy or neuromodulation for generalized or multifocal epilepsy. Original schematic.

1. Drug-resistant epilepsy

2. Why operate early

3. Etiologies

4. Outcomes

Related topics

References

  1. Dwivedi R, Ramanujam B, Chandra PS, et al. Surgery for drug-resistant epilepsy in children. N Engl J Med 2017;377(17):1639–1647. doi:10.1056/NEJMoa1615335. PMID 29069568. verified
  2. Samanta D, Caraway AR, Knox AT, et al. Delayed surgical evaluation after drug-resistant epilepsy diagnosis worsens outcomes in children: a multicenter study. Neurol Clin Pract 2026;16(5):e200641. doi:10.1212/CPJ.0000000000200641. PMID 42479984. verified
  3. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51(6):1069–1077. doi:10.1111/j.1528-1167.2009.02397.x. PMID 19889013. verified
  4. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342(5):314–319. doi:10.1056/NEJM200002033420503. PMID 10660394. verified
  5. Berg AT, Shinnar S, Levy SR, et al. Early development of intractable epilepsy in children: a prospective study. Neurology 2001;56(11):1445–1452. doi:10.1212/wnl.56.11.1445. PMID 11402099. verified
  6. Spooner CG, Berkovic SF, Mitchell LA, et al. New-onset temporal lobe epilepsy in children: lesion on MRI predicts poor seizure outcome. Neurology 2006;67(12):2147–2153. doi:10.1212/01.wnl.0000248189.93630.4f. PMID 17082466. verified
  7. Jehi L, Jette N, Kwon CS, et al. Timing of referral to evaluate for epilepsy surgery: expert consensus recommendations from the Surgical Therapies Commission of the International League Against Epilepsy. Epilepsia 2022;63(10):2491–2506. doi:10.1111/epi.17350. PMID 35842919. verified
  8. Englot DJ, Jehi L. ILAE position on early surgery for drug sensitive lesional focal epilepsy. Brain 2025;148(11):e108. doi:10.1093/brain/awaf266. PMID 40681963. verified
  9. Cormack F, Cross JH, Isaacs E, et al. The development of intellectual abilities in pediatric temporal lobe epilepsy. Epilepsia 2007;48(1):201–204. doi:10.1111/j.1528-1167.2006.00904.x. PMID 17241230. verified
  10. Loddenkemper T, Holland KD, Stanford LD, et al. Developmental outcome after epilepsy surgery in infancy. Pediatrics 2007;119(5):930–935. doi:10.1542/peds.2006-2530. PMID 17473093. verified
  11. Jobst BC, Bergey G, Roldán-Benítez YM, et al. American Epilepsy Society/Congress of Neurological Surgeons epilepsy surgery clinical practice guideline. Epilepsy Curr 2026. doi:10.1177/15357597261465347. PMID 42948139. verified
  12. Harvey AS, Cross JH, Shinnar S, et al. Defining the spectrum of international practice in pediatric epilepsy surgery patients. Epilepsia 2008;49(1):146–155. doi:10.1111/j.1528-1167.2007.01421.x. PMID 18042232. verified
  13. Lerner JT, Salamon N, Hauptman JS, et al. Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. Epilepsia 2009;50(6):1310–1335. doi:10.1111/j.1528-1167.2008.01998.x. PMID 19175385. verified
  14. Weiner HL, Carlson C, Ridgway EB, et al. Epilepsy surgery in young children with tuberous sclerosis: results of a novel approach. Pediatrics 2006;117(5):1494–1502. doi:10.1542/peds.2005-1206. PMID 16651302. verified
  15. Widjaja E, Jain P, Demoe L, et al. Seizure outcome of pediatric epilepsy surgery: systematic review and meta-analyses. Neurology 2020;94(7):311–321. doi:10.1212/WNL.0000000000008966. PMID 31996452. verified
  16. Téllez-Zenteno JF, Dhar R, Wiebe S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain 2005;128(Pt 5):1188–1198. doi:10.1093/brain/awh449. PMID 15758038. verified
  17. Téllez-Zenteno JF, Dhar R, Hernandez-Ronquillo L, Wiebe S. Long-term outcomes in epilepsy surgery: antiepileptic drugs, mortality, cognitive and psychosocial aspects. Brain 2007;130(Pt 2):334–345. doi:10.1093/brain/awl316. PMID 17124190. verified

Verification (2026-11-16):

Caveats: